Number of cycles of induction chemotherapy received and aggregate hospital bed days associated with first-line therapy
| Group . | (1) . | (2) . | (3) . | (4) . | Total . | P value 4-group . | Group (1) vs (4) . |
|---|---|---|---|---|---|---|---|
| RHCVAD, n = 83, N (%) . | RHCVAD + HDT/ASCR, n = 21, N (%) . | RCHOP, n = 29, N (%) . | RCHOP + HDT/ASCR, n = 34, N (%) . | ||||
| Cycles of induction received | |||||||
| 1-3 | 6 (8) | 2 (9) | 2 (8) | 0 (0) | 10 (6) | ||
| 3-5 | 10 (13) | 12 (57) | 2 (8) | 2 (6) | 26 (17) | ||
| 6 | 49 (64) | 5 (24) | 15 (60) | 26 (79) | 95 (61) | ||
| 7 | 4 (5) | 0 (0) | 2 (8) | 4 (12) | 10 (6) | ||
| 8-10 | 8 (10) | 2 (9) | 4 (16) | 1 (3) | 15 (10) | NR | NR |
| Unknown | 3 | 0 | 1 | 1 | 5 | ||
| Hospital days associated with first-line therapy | |||||||
| 0 | 0 | 0 | 16 (55) | 0 | 16 (11) | ||
| 1-15 | 16 (22) | 0 | 11 (38) | 0 | 27 (18) | ||
| 15-30 | 21 (30) | 0 | 1 (3) | 27 (87) | 49 (33) | ||
| 30-45 | 29 (41) | 5 (31) | 0 | 3 (10) | 37 (25) | ||
| 45+ | 5 (7) | 11 (69) | 1 (3) | 1 (3) | 18 (12) | NR | NR |
| Unknown* | 12 | 5 | 0 | 3 | 20 | ||
| Median | 29 d | 53 d | 0 d | 23 d | < 0.001†‡ | 0.05§‖ |
| Group . | (1) . | (2) . | (3) . | (4) . | Total . | P value 4-group . | Group (1) vs (4) . |
|---|---|---|---|---|---|---|---|
| RHCVAD, n = 83, N (%) . | RHCVAD + HDT/ASCR, n = 21, N (%) . | RCHOP, n = 29, N (%) . | RCHOP + HDT/ASCR, n = 34, N (%) . | ||||
| Cycles of induction received | |||||||
| 1-3 | 6 (8) | 2 (9) | 2 (8) | 0 (0) | 10 (6) | ||
| 3-5 | 10 (13) | 12 (57) | 2 (8) | 2 (6) | 26 (17) | ||
| 6 | 49 (64) | 5 (24) | 15 (60) | 26 (79) | 95 (61) | ||
| 7 | 4 (5) | 0 (0) | 2 (8) | 4 (12) | 10 (6) | ||
| 8-10 | 8 (10) | 2 (9) | 4 (16) | 1 (3) | 15 (10) | NR | NR |
| Unknown | 3 | 0 | 1 | 1 | 5 | ||
| Hospital days associated with first-line therapy | |||||||
| 0 | 0 | 0 | 16 (55) | 0 | 16 (11) | ||
| 1-15 | 16 (22) | 0 | 11 (38) | 0 | 27 (18) | ||
| 15-30 | 21 (30) | 0 | 1 (3) | 27 (87) | 49 (33) | ||
| 30-45 | 29 (41) | 5 (31) | 0 | 3 (10) | 37 (25) | ||
| 45+ | 5 (7) | 11 (69) | 1 (3) | 1 (3) | 18 (12) | NR | NR |
| Unknown* | 12 | 5 | 0 | 3 | 20 | ||
| Median | 29 d | 53 d | 0 d | 23 d | < 0.001†‡ | 0.05§‖ |
For patients receiving RCHOP induction, total cycles of therapy include cycles of sequential therapy received. Patients progressing while on induction therapy (n = 6) were excluded from the analysis involving cycles of therapy.
NR indicates not reported. Other abbreviations are explained in Table 1.
Unknown hospital days include patients for whom admission records were inaccessible. P values reflect the difference in median hospital days between the 4 groups (4-group) or between the RHCVAD and RCHOP + HDT/ASCR groups (group 1 vs 4).
P < .001.
Kruskal-Wallis test.
P < .05.
Mann-Whitney U test.